126 related articles for article (PubMed ID: 24955936)
1. A 36 month naturalistic retrospective study of clinic-treated youth with attention-deficit/hyperactivity disorder.
Hong M; Lee WH; Moon DS; Lee SM; Chung US; Bahn GH
J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):341-6. PubMed ID: 24955936
[TBL] [Abstract][Full Text] [Related]
2. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
[TBL] [Abstract][Full Text] [Related]
3. Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate.
Wang LJ; Chen CK; Huang YS
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):246-53. PubMed ID: 25574708
[TBL] [Abstract][Full Text] [Related]
4. Medication persistence in Turkish children and adolescents with attention-deficit/hyperactivity disorder.
Ayaz M; Ayaz AB; Soylu N; Yüksel S
J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):442-7. PubMed ID: 25010598
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study.
Atzori P; Usala T; Carucci S; Danjou F; Zuddas A
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):673-81. PubMed ID: 20035585
[TBL] [Abstract][Full Text] [Related]
6. When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations.
Manor I; Rozen S; Zemishlani Z; Weizman A; Zalsman G
Clin Neuropharmacol; 2011; 34(4):148-54. PubMed ID: 21738027
[TBL] [Abstract][Full Text] [Related]
7. Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
Yılmaz S; Bilgiç A; Hergüner S
J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):158-60. PubMed ID: 24168715
[TBL] [Abstract][Full Text] [Related]
8. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
9. Naturalistic Pharmacotherapy Compliance among Pediatric Patients with Attention Deficit/Hyperactivity Disorder: a Study Based on Three-Year Nationwide Data.
Hong M; Kim B; Hwang JW; Bhang SY; Choi HY; Oh IH; Lee YJ; Bahn GH
J Korean Med Sci; 2016 Apr; 31(4):611-6. PubMed ID: 27051247
[TBL] [Abstract][Full Text] [Related]
10. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
[TBL] [Abstract][Full Text] [Related]
11. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
[TBL] [Abstract][Full Text] [Related]
12. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
13. Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorder.
Hwang JW; Kim B; Kim Y; Kim TH; Seo WS; Shin DW; Woo YJ; Yoo H; Lee JS; Lee JH; Lim MH; Chung YC; Jung CH; Yoo HK
Hum Psychopharmacol; 2013 Nov; 28(6):600-7. PubMed ID: 24519694
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
Moungnoi P; Maipang P
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S158-63. PubMed ID: 22043770
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
[TBL] [Abstract][Full Text] [Related]
16. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
Schertz M; Adesman AR; Alfieri NE; Bienkowski RS
Pediatrics; 1996 Oct; 98(4 Pt 1):763-9. PubMed ID: 8885958
[TBL] [Abstract][Full Text] [Related]
17. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
18. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
[TBL] [Abstract][Full Text] [Related]
20. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.
Wilens T; Pelham W; Stein M; Conners CK; Abikoff H; Atkins M; August G; Greenhill L; McBurnett K; Palumbo D; Swanson J; Wolraich M
J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):424-33. PubMed ID: 12649629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
